Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1989 1
1990 2
1991 1
1999 2
2001 1
2002 2
2003 1
2004 2
2006 5
2007 1
2008 4
2009 5
2010 4
2011 2
2012 4
2013 8
2014 13
2015 12
2016 4
2017 11
2018 11
2019 15
2020 13
2021 19
2022 24
2023 18
2024 28
2025 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

217 results

Results by year

Filters applied: . Clear all
Page 1
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
Allen JA, Lin J, Basta I, Dysgaard T, Eggers C, Guptill JT, Gwathmey KG, Hewamadduma C, Hofman E, Hussain YM, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu MA, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis RA, van Doorn PA; ADHERE Study Group. Allen JA, et al. Lancet Neurol. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0. Lancet Neurol. 2024. PMID: 39304241 Clinical Trial.
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis.
Qin C, Dong MH, Zhou LQ, Chu YH, Pang XW, He JY, Shang K, Xiao J, Zhu L, Ye H, Cai SB, Wang D, Bu BT, Meyer Zu Hörste G, Li CR, Tian DS, Wang W. Qin C, et al. Among authors: bu bt. Cell. 2025 Nov 13;188(23):6414-6423.e11. doi: 10.1016/j.cell.2025.09.020. Epub 2025 Oct 15. Cell. 2025. PMID: 41101309 Free article. Clinical Trial.
Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China.
Luo S, Jiang Q, Zeng W, Wang Q, Zou Z, Yu Y, Hong D, Zeng Q, Tan S, Zhang Z, Zhang Y, Guo X, Chen J, Zhao Z, Huang S, Shi J, Chen Y, Du L, Yan C, Xi J, Song J, Zhao C; Chinese Myasthenia Gravis Collaborating Group (CMGCG). Luo S, et al. Ann Clin Transl Neurol. 2024 Aug;11(8):2212-2221. doi: 10.1002/acn3.52142. Epub 2024 Jul 7. Ann Clin Transl Neurol. 2024. PMID: 38973109 Free PMC article.
Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.
Qin C, Tian DS, Zhou LQ, Shang K, Huang L, Dong MH, You YF, Xiao J, Xiong Y, Wang W, Pang H, Guo JJ, Cai SB, Wang D, Li CR, Zhang M, Bu BT, Wang W. Qin C, et al. Among authors: bu bt. Signal Transduct Target Ther. 2023 Jan 4;8(1):5. doi: 10.1038/s41392-022-01278-3. Signal Transduct Target Ther. 2023. PMID: 36596762 Free PMC article. Clinical Trial.
Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial.
Yan C, Yue Y, Guan Y, Bu B, Ke Q, Duan R, Deng H, Xue Q, Jiang H, Xiao F, Yang H, Chang T, Zou Z, Li H, Tan S, Xiao H, Zhou H, Zhang H, Meng Q, Li W, Li W, Guo J, Zhang Y, Li Z, Tu J, Shi J, Li W, Lee M, Chen Y, Tao X, Zhao S, Li P, Zhao C; Batoclimab Study Team. Yan C, et al. Among authors: bu b. JAMA Neurol. 2024 Mar 4;81(4):336-45. doi: 10.1001/jamaneurol.2024.0044. Online ahead of print. JAMA Neurol. 2024. PMID: 38436998 Free PMC article.
217 results